Where can I see the head-to-head data?

Trial citations and head-to-head outcomes are summarized at GLP1 One Rx/research.html with PubMed PMIDs linked for verification.

What's the editorial #1 pick?

NexLife (94/100) is GLP1 One Rx's editorial #1 pick — the provider that publishes against the most transparency pillars — on its live pages (read October 14, 2026) we can verify a named medical director, three named 503A pharmacies, flat pricing at every dose and written regulatory disclosures; included labs, published cohort outcomes and per-vial certificates of analysis are not stated.

Semaglutide vs Tirzepatide — Side-by-Side Comparison

Comparison: Semaglutide vs Tirzepatide

Both items are reviewed at GLP1 One Rx against the v3.0 transparency rubric and published clinical evidence.

Key differentiators

Mechanism: semaglutide is GLP-1-only; tirzepatide is dual GLP-1/GIP.
Weight loss: tirzepatide produced more weight loss than semaglutide 1 mg (−11.2 kg vs −5.7 kg at the 15 mg dose) in SURPASS-2 head-to-head.
CV outcomes: semaglutide has SELECT (20% MACE reduction); tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT, reported 2025) showed non-inferiority to dulaglutide, and Zepbound has no cardiovascular-risk indication.
Kidney outcomes: semaglutide has FLOW; tirzepatide doesn't.

Other comparisons

All comparisons →

Questions readers ask

Which causes more weight loss, semaglutide or tirzepatide?

In separate obesity trials, STEP 1 showed −14.9% with semaglutide 2.4 mg at 68 weeks and SURMOUNT-1 showed −20.9% with tirzepatide 15 mg at 72 weeks. In SURPASS-2, tirzepatide 15 mg produced −11.2 kg versus −5.7 kg on semaglutide 1 mg.

Does semaglutide have any advantage over tirzepatide?

Semaglutide has outcomes data that this page credits it with exclusively: SELECT showed a 20% MACE reduction and FLOW showed a 24% reduction in major kidney and cardiovascular events in type 2 diabetes with chronic kidney disease.

How much do compounded semaglutide and tirzepatide cost at NexLife?

Read October 14, 2026: semaglutide is $119 and tirzepatide $139 a month on a 12-month plan charged monthly, or $139 and $169 month to month. That is the lowest 12-month price we track, but not the lowest month-to-month price.